ASC930

Phase 2Biologic

AASC Therapeutics

ASC930 is one of 40 biologic programs targeting Acute Graft Versus Host Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Graft Versus Host DiseaseActive, not recruiting

Acute Graft Versus Host DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

54 competitors in Acute Graft Versus Host Disease

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Phase 3

8 2

Entyvio

Takeda

Phase 3

1 3

Enbrel

IImmunex

Phase 3

3 4

8-Mop

TTherakos, Inc., a Mallinckrodt Company

Phase 3

2 5

Medrol

Pfizer

Phase 2

9 6

Cellcept

Roche

Phase 2

8 7

Nipent

Pfizer

Phase 2

2 8

Epidiolex

Jazz Pharmaceuticals

Phase 2

2 9

Neoral

Novartis

Phase 2

1 10

Rapamune

PPrism Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Graft Versus Host Disease1 trial

ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Not yet recruiting·AASC Therapeutics·Phase 2·NCT04883918·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ASC930. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ASC930 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ASC930. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ASC Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: AASC Therapeutics

ASC930

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Graft Versus Host Disease1 trial

References

Drug Info

Quick Facts

Related News